Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Aurinia Pharma: Capital raise increases the chances for inking an economically lucrative partnership deal — FBR & Co. yesterday (7.90)FBR & Co yesterday noted AUPH strengthened its bargaining position at a prospective table of would-be partners and/or acquirers with the secondary. They estimate AUPH could net $138M in proceeds, which could be sufficient to fully fund the completion of the planned AURORA Phase III trial with voclosporin (VCS) in lupus nephritis (LN) patients (est. start 2Q17). They look for the signing of a partnership deal worth in the range of $500M to $700M in up-front and milestone payments to AUPH. They look for AUPH to sign with a Big Pharma company in the next three to six months, which could be a positive catalyst for the stock. They think a partnership is more likely than an acquisition, however, as they project VCS could achieve >$2B in annual peak sales; they could see a bid in the next six to nine months.</td> </tr></table>"